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Background: Cross-sectional measures of body mass index (BMI) 
are associated with cardiovascular disease (CVD) incidence, but less 
is known about whether weight change affects the risk of CVD.
Methods: We estimated the effect of 2-y weight change interven-
tions on 7-y risk of CVD (CVD death, myocardial infarction, stroke, 
hospitalization from coronary heart disease, and heart failure) by 
emulating hypothetical interventions using electronic health records. 
We identified 138,567 individuals with 45–69 years of age without 
chronic disease in England from 1998 to 2016. We performed pooled 
logistic regression, using inverse-probability weighting to adjust for 
baseline and time-varying confounders. We categorized each indi-
vidual into a weight loss, maintenance, or gain group.
Results: Among those of normal weight, both weight loss [risk differ-
ence (RD) vs. weight maintenance = 1.5% (0.3% to 3.0%)] and gain 
[RD = 1.3% (0.5% to 2.2%)] were associated with increased risk for 
CVD compared with weight maintenance. Among overweight individu-
als, we observed moderately higher risk of CVD in both the weight loss 
[RD = 0.7% (−0.2% to 1.7%)] and the weight gain group [RD = 0.7% 
(−0.1% to 1.7%)], compared with maintenance. In the obese, those losing 
weight showed lower risk of coronary heart disease [RD = −1.4% (−2.4% 
to −0.6%)] but not of stroke. When we assumed that chronic disease 
occurred 1–3 years before the recorded date, estimates for weight loss 
and gain were attenuated among overweight individuals; estimates for 
loss were lower among obese individuals.
Conclusion: Among individuals with obesity, the weight-loss group 
had a lower risk of coronary heart disease but not of stroke. Weight 
gain was associated with increased risk of CVD across BMI groups. 
See video abstract at, http://links.lww.com/EDE/B838.
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INTRODUCTION
Lifestyle1 and pharmacotherapy interventions2,3 have 
been shown in randomized controlled trials (RCTs) to be 
effective in achieving weight loss among individuals with 
overweight or obesity. In such high-risk patients, there is evi-
dence that weight loss is also beneficial for cardiovascular risk 
factors.4 However, there are mixed findings on the effect of 
weight loss on cardiovascular disease (CVD), as some studies 
found no effect of weight loss on CVD,1,5,6 although a recent 
meta-analysis of trials reported moderate lower risk of CVD 
following weight loss.4 In any case, there are no RCTs of any 
weight-loss intervention assessing the effectiveness for pri-
mary prevention of CVDs in otherwise healthy individuals 
with overweight or obesity. This is particularly important as 
higher body mass index (BMI) is associated with the onset 
of cardiovascular diseases,7 and the prevalence of obesity, 
already high, is predicted to increase further.8
Emulating target pragmatic trials using causal inference 
methods in large-scale observational data may play a role in 
distinguishing effects of weight change in people with normal 
weight, overweight, and obesity.9-12 Observational studies of 
weight or BMI change are conflicting, with studies report-
ing variously increased risk of CVD,13-16 no association,17-19 
or lower risk. Studies looking at people with severe obesity 
who had bariatric surgery experienced particular reductions in 
risk.20 Weight gain has been associated with increased CVD 
risk in some studies,13-16 but not others.21 The Nurses’ Health 
Study has emulated weight-loss trials (i.e., in a consented 
cohort), which found no relationship between weight loss 
and CHD.17,18 To our knowledge, there have been no previ-
ous emulation of weight-loss trials reporting separate effects 
within groups of people with normal weight, overweight, or 
obesity. This distinction is very important because weight loss 
might be more beneficial for individuals with obesity20 than 
for overweight individuals,19 although weight loss might have 
adverse effects on CVD in normal-weight individuals.13
In this study, we investigated hypothetical interventions 
using electronic health records (EHR) and assessed whether 
weight change affects the occurrence of CVDs. This is to our 
knowledge the largest study (~138 K) to estimate the effect of 
weight change on CVDs in individuals with 45–69 years of 
age and the first one to investigate weight change separately in 




We analyzed data from individuals from the CALIBER 
programme in England between January 1, 1998, and June 
30, 2016. CALIBER links anonymized coded EHR from three 
national data sources of patients across primary care (Clinical 
Practice Research Datalink), hospital care (Hospital Episode 
Statistics), and death registry (Office of National Statistics), 
from a large sample, representative of the population of 
England.22 Methods for the development of reproducible phe-
notypes and metadata have been described previously23 and 
are available online (www.caliberresearch.org/portal). The 
study was approved by the Independent Scientific Advisory 
Committee (ISAC) of the Medicines and Healthcare Products 
Regulatory Agency (United Kingdom).
Covariates
Height and weight measurements were based on pri-
mary care records and measured as part of routine care. We 
divided our sample into three groups based on standard clini-
cal BMI cutoffs: individuals with (i) normal weight (18.5–
24.9 kg/m2), (ii) overweight (25–29.9 kg/m2), and (iii) obesity 
(30–39.9 kg/m2).
We also used information on the following variables: 
age at baseline, sex, region, index of multiple deprivations 
(IMD), ethnicity, smoking status, physical activity, diabe-
tes, cancer (apart from nonmelanoma skin cancer), demen-
tia, severe mental diseases, chronic kidney disease, chronic 
obstructive pulmonary disease, HIV, major inflammatory 
diseases, Parkinson’s disease, multiple sclerosis, renal failure 
(or initiation of dialysis), prevalence of hypertension, antihy-
pertensive medication, number of weight measurements, and 
number of clinical consultations every year.
Target Trials Specification and Emulation
We first explicitly specified the target trials of interest 
and then used EHR to emulate them.9-12 We present the pro-
tocol of the target trial, along with the protocol of the trial 
emulation below, in Table 1, and we provide further details in 
the eAppendix (Section 2); http://links.lww.com/EDE/B828.
Protocol of the Target Trial
Eligibility criteria. We included individuals aged 45–69 
years old, from primary care practices in England registered 
between 1998 and 2016 without the following chronic dis-
eases: cardiovascular disease, diabetes, cancer (apart from 
nonmelanoma skin cancer), dementia, severe mental diseases, 
chronic kidney disease, chronic obstructive pulmonary dis-
ease, HIV and major inflammatory diseases.
Treatment strategies. Three weight change interventions 
were applied for 2 years.
(a) loss: ≥3% and <20% of bodyweight each year or 
undergo bariatric surgery.
(b) weight maintenance: >−3% and <3% of bodyweight 
change each year.
(c) gain: ≥3% and <20% of bodyweight each year.
These strategies are not prespecified; in other words, 
body weight may change via. different interventions (e.g., 
physical activity and diet). We further discuss this point in the 
Discussion.
Treatment assignment. At random
Follow-up. 7 years
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Outcomes. The primary outcome is a composite CVD 
(CVD death, myocardial infarction, stroke, hospitalization from 
CHD and heart failure). The secondary outcomes were composite 
CHD, myocardial infarction, stroke, heart failure, CVD deaths.
Causal contrasts. We are interested in the per-protocol 
effect, that is, the effect of these interventions on CVD, had all 
individuals adhered to their assigned interventions for both 
the first and the second year.
Analysis plan. To estimate the per-protocol effect of 
these 2-year interventions, we would first break all the follow-
up time of each individual into 1-year periods. We would then 
have to account for all pre- and postrandomization factors that 
TABLE 1. Specification and Emulation of Target Trials to Estimate the Effect of Weight Change on Various CVD Outcomes. 
Description for the three main trials in normal weight, overweight and obese individuals
 Target Trials




Trials would enroll healthya individuals at baseline in England, aged 45–69 years old 
between 1998 and 2016. We would exclude participants who would have undergone 
bariatric surgery before baseline or who would be unhealthya before baseline. The 
trials will be conducted in different population groups by BMI levels (different trials 
for normal weight, overweight, and obese people).
Baseline is defined as the date of the first BMI and weight observations, given that all 
eligibility criteria are met.
Same plus: (i) all participants should have measure-
ments of smoking status. Especially for those 
individuals with information on both physical 
activity and smoking status, we selected as base-
line date, the date of the first BMI, and weight 
observations, in which they had information on 
both smoking status and physical activity.
(ii)  emulated trial applied the exclusion criteria from 
chronic diseases based on observing a 12-month 
baseline period and(iii) excluded individuals 
who had ≥12 clinical consultations or measured 
their bodyweight ≥6 times in the primary careb 
during the baseline period (first year)
Treatment 
strategies
(a) lose 3–20% of their weight each year or undergo bariatric surgery
(b) maintain their weight, (weight change >−3% and <3% of bodyweight each year)
(c) gain 3–20% of their weight each year
These hypothetical interventions will be followed for 2 years. Individuals were free to 
deviate after the end of the second year. Individuals would be allowed to deviate from 
their assigned intervention if they developed clinically allowable reasons for deviating 
from assigned intervention
Same + Individuals are allowed to deviate from their 
assigned intervention if they have ≥12 clinical 
consultations or measured their body weight ≥6 




Individuals would be randomly assigned to a strategy at baseline and will be aware of 
the strategy to which they have been assigned.
Randomization is emulated via. adjustment for 




Starts at baseline and ends at CVD diagnosis, death, loss to follow-up (transfer out, 7 years 
after baseline, or administrative end of follow-up (31 June 2016), whichever occurs first.
Same
Endpoints Primary endpoint:
Composite CVD outcome (CVD deaths, nonfatal Myocardial infarction, nonfatal stroke, 
hospitalization from coronary heart disease, hospitalization from heart failure)
Secondary endpoints:
(a)  Composite CHD outcome (CHD deaths, nonfatal Myocardial infarction, hospitaliza-
tion from CHD)
(b) Myocardial infarction, (c) fatal and nonfatal Stroke and
(d) heart failure (hospitalizations or deaths), and (e) CVD deaths
Same + sensitivity analysis for
(a) diabetes (positive control outcome)
(b)  nonmelanoma skin cancer (negative control 
outcome)
Causal contrast Per-protocol effect, i.e., effect of adhering to assigned strategy on CVD onset Observational analog of the per-protocol effects
Analysis plan To estimate the per-protocol effect, we would adjust for pre- and postrandomization fac-
tors associated with adherence and loss to follow-up via. IPW
Subgroup analyses by baseline age (<60 and ≥60 years old) and sex (males and females).
Same plus additional adjustment for baseline covari-
ates in the outcome regression
aThe healthy participants should have no prevalent chronic disease. The set of chronic disease we used was cardiovascular disease, diabetes, cancer (apart from nonmelanoma skin 
cancer), dementia, severe mental diseases (acute stress, phobia, anxiety, depression, schizophrenia, bipolar disorder, and affective disorder), chronic kidney disease, chronic obstructive 
pulmonary disease, HIV, major inflammatory diseases, Parkinson’s disease, multiple sclerosis, and renal failure.
bWe considered individuals who had ≥12 clinical consultations or measured their body weight ≥6 times per year as unhealthy.
cIn the outcome regression models, we adjust for following variables at baseline; age, sex, region (in 8 categories), family history of CVD, BMI. We additionally adjusted for 
prevalence of hypertension, high LDL measurement before baseline, use of diuretics before baseline, number of weight measurement during the first year (in categories; 1:1 time, 2:2 
times, 3:3–5 times), smoking status during the first year (never, former, current), number of clinical consultations during the first year (ordered; 1:≤2 times, 2:3–5 times, 3:6–8 times, 
and 4:8–11 times).
BMI indicates body mass index; CVD, cardiovascular disease, CHD, coronary heart disease.
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were related to adherence for the first and the second year, 
using an inverse probability for treatment weights (IPTW). 
With this procedure, we weight each observation by the 
inverse of the probability of an individual having adhered 
to his or her assigned weight change intervention, given his 
or her past intervention and prognostic factors history. We 
explain in detail this procedure in the statistical analysis of the 
emulated trials.
Protocol of the Emulated Trial
Eligibility criteria. Same as the target trial plus the fol-
lowing modifications: (i) all participants should have mea-
surements of smoking status (important confounder). (ii) 
Although the target trial would apply eligibility criteria and 
assign treatment strategies at a unified time zero, our emu-
lated trial applies the exclusion criteria from chronic diseases 
based on observing a 12-month baseline period. (iii) We also 
excluded individuals who had ≥12 clinical consultations or 
measured their body weight at least six times in the primary 
care setting during the first year.
Treatment strategies. Same as for the target trial
Treatment assignment. Individuals are not initially ran-
domized. We classified each individual into the weight loss, 
maintenance, and gain groups, according to their observed 
weight trajectories during the first year of follow-up
Follow-up. 7 years
Outcomes. Same as the target trial plus sensitivity anal-
ysis using diabetes as a positive control outcome and nonmel-
anoma skin cancer as a negative control outcome. We discuss 
in detail the use of positive and negative control outcome in 
the sensitivity analysis
Causal contrasts. Same as for the target trial
Analysis plan. We additionally adjusted for confounders 
in the baseline period to emulate baseline randomization. See 
details below.
Statistical Analysis of the Emulated Trials
Pooled logistic regression models were used to estimate 
the hazard ratios of the hypothetical interventions and the 
cumulative incidence risk curves of each intervention,9 after 
dividing the 7-year follow-up time into 1-year periods. Time 
of entry in the emulated trials was considered the date of the 
first BMI observations. Each time point corresponds to 1-year 
duration of our interventions. To emulate randomization in 
the baseline period, we adjusted for: age (in years), sex (man/
woman), BMI (in kg/m2), prevalence of hypertension (yes/
no), record of high LDL levels (before baseline; yes/no), use 
of diuretics before baseline (yes/no), family history of CVD 
(yes/no), hypertension during the first year (yes/no); high LDL 
levels during the first year (yes/no), use of diuretics during the 
first year (yes/no), smoking status during the first year (never, 
former and current), bodyweight measurements during the 
first year (categorical: 1, 2, and 3–5 measurements), clinical 
consultations during the first year (categorical: 1–2, 3–5, 6–8, 
and 9–11 consultations), and region (categorical; London, 
South West, South Central, South East, East, West Midlands, 
Central North and North West). Nonadherence occurred when 
individuals were assigned to a particular weight change group 
in the first year but deviated from it in the second year. We 
used IPTW to adjust for time-fixed and time-dependent con-
founders9,12 that were related to adherence in the second year. 
To calculate the denominator of the IPTW, we used multino-
mial logistic regression models to model weight loss, mainte-
nance, and gain in the second year, as a function of prognostic 
factors measured before baseline, during the first and second 
year of these interventions, along with the observed weight 
change intervention of the first year. These weights remained 
unchanged after the second year because we were interested 
in the effect of interventions sustained over 2 years only. 
After calculating the IPTW for the received intervention in 
the second year, individuals were then censored during the 
second year if they deviate from their assigned intervention. 
Individuals who developed a chronic disease other than CVD 
during the second year (and thus were allowed to deviate from 
their intervention) were assigned the weight of 1 across all 
time points. We note that we used the nonstabilized IPTW 
because the regime of the trials was dynamic12 (as there are 
clinically allowable reasons after which individuals were free 
to deviate from their initial intervention).
We also adjusted for pre- and postrandomization prog-
nostic factors of loss to follow-up through inverse probability 
of censoring weighting (IPCW) to estimate the effect of the 
interventions had individuals remained uncensored during the 
follow-up.12 IPTW and IPCW specific to each time point were 
multiplied to create time-specific weights. The final weight for 
each individual at a specific time was the cumulative product 
of his/her time-specific weights up until that time point. We 
truncated weights >15 (and higher than the 99th percentile of 
weights) and set them to 15.
We estimated incidence risk curves by fitting the 
weighted pooled logistic regression models, by additionally 
including product terms between intervention and follow-up 
time (linear, squared, and cubic time) to allow for time-vary-
ing effects (see eAppendix [Section 3]; http://links.lww.com/
EDE/B828). We did not include these product terms in the 
calculation of hazard ratios, and hence this part of the analy-
sis relied on the proportional hazard assumption. Finally, we 
used robust variance estimators to calculate 95% confidence 
intervals (CI) for the hazard ratio estimates and nonparamet-
ric bootstrapping from 500 samples to obtain percentile-based 
95% CI for the cumulative incidence estimates.
Sensitivity Analysis
We used positive and negative control outcomes 
because any deviation from the expected associations would 
help us detect potential biases in our emulated trials. In 
the analysis of the positive control outcome, we expect to 
observe a nonnull relationship between the exposure and 
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the outcome, although, in the analysis of the negative con-
trol outcome, we anticipate estimating no association. We 
expected that weight loss would be related to lower diabe-
tes risk and weight gain to higher diabetes risk.24 We chose 
nonmelanoma skin cancer as a negative control outcome 
because there is no established connection between weight 
change and nonmelanoma skin cancer.
To examine whether results were affected by unac-
counted confounders, we redefined the eligibility criteria 
to individuals by additionally requiring that individuals 
had measurements of IMD, ethnicity, and physical activ-
ity (assuming that last observation carries forward for 4 
years). We took these variables into account when adjust-
ing the pooled logistic regression (to emulate randomiza-
tion) and when estimating the IP weights. We also applied 
subgroup analysis by age and sex, and we repeated the 
analysis1 using different cutoffs for the weight gain (3%–
10% gain per year) and loss (3%–10% loss per year) arms,2 
after additionally adjusting for calendar year,3 and in the 
obese nonsmokers only.
Moreover, to take into consideration potential preclini-
cal diseases, we assumed that a chronic disease (from the 
set that was described in the inclusion criteria of the target 
trial) occurred 1, 2, or 3 years before it was recorded during 
follow-up and assessed whether estimates were robust to this 
decision.
RESULTS
Of 1,161,264 individuals aged 45–69, in the primary 
care database with BMI and weight measurements between 
1 January 1998 and 30 May 2016, 138,567 were eligible 
for the hypothetical trials conducted separately in individu-
als with normal weight, overweight, and obesity (Figure 1). 
Specifically, the emulated trials included 45,938 normal 
weight, 57,682 overweight and 34,947 individuals with obe-
sity. Additionally, in Table 2, we observed that the percentage 
of individuals who adhered to their assigned intervention dur-
ing the second year was much higher in the weight mainte-
nance group in all three trials compared with the other arms. 
In the weight maintenance group, the percentage of women 
was lower compared with the other two groups. Additionally, 
individuals in the weight maintenance group had fewer clini-
cal consultations and had their weight measured within pri-
mary care less frequently during the first year.
Emulated Trials in the Normal Weight
Among normal-weight individuals, those in the weight 
loss and weight gain groups had a higher risk for the composite 
FIGURE 1. CONSORT diagram—Emulating 2-year weight change interventions in normal weight, overweight, and obese 
individuals.
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CVD outcome (Figure 2). The risk difference (RD) for weight 
loss vs. maintenance was 1.5% (0.3% to 3.0%)] and gain ver-
sus maintenance was RD = 1.3% (0.5% to 2.2%). Compared 
with weight maintenance, the hazard ratios for weight loss 
were 1.53 (1.18–1.98) and for weight gain 1.43 (1.19–1.71). 
A similar pattern was observed for most of the secondary out-
comes (Figure 3). Estimates were similar in subgroups of indi-
viduals defined at baseline according to age, but different for 
females compared to males (HR = 1.72 [1.22–2.41] for men, 
HR = 1.28 [0.84–1.96] for women, comparing weight loss to 
weight maintenance) (see eAppendix and eFigure 1; http://
links.lww.com/EDE/B828). In sensitivity analyses, estimates 
were similar with additional adjustment for IMD, ethnicity or 
physical activity (see eAppendix and eFigure 2; http://links.
lww.com/EDE/B828). Estimates were also similar when we 
assumed that a set of chronic diseases occurred 1, 2, or 3 years 
before they were recorded in the database (see Figure 2 and 
eFigure 3; http://links.lww.com/EDE/B828).
Emulated Trials in the Overweight
Among individuals with overweight, those in the weight 
loss and weight gain groups had a higher risk for CVD, com-
pared with those in the weight maintenance groups (HR = 1.20 
[0.99–1.44] for weight loss and 1.17 [0.99–1.38] for weight 
gain; Figure 2). In Figure 4, the 7-year RD of CVD for weight 
loss versus maintenance was 0.7% (−0.2% to 1.7%) and for 
weight gain versus maintenance was 0.7% (−0.1% to 1.7%). 
Estimates were similar with additional adjustment for IMD, 
ethnicity, or physical activity (see eAppendix and eFigure 4; 
http://links.lww.com/EDE/B828) and in subgroup analyses by 
age and sex (see eAppendix and eFigure 4; http://links.lww.
com/EDE/B828). However, we did observe some differences 
when considering that chronic diseases occurred 1, 2, or 3 
years before the recorded diagnosis date. Estimates for weight 
loss and weight gain (vs. weight maintenance) were attenuated 
with increasing lags for chronic disease records (Figure 2 and 
eAppendix and eFigure 3; http://links.lww.com/EDE/B828).
Emulated Trials in Individuals With Obesity
Among individuals with obesity, those in the weight gain 
group had a higher risk for CVD compared with those in the 
maintenance group (Figure  2; HR = 1.31 [1.07–1.60]). The 
hazard ratio of CVD for weight loss versus maintenance was 
0.90 (0.72–1.13). In the analysis of the secondary outcomes 
(Figure 3), those in the weight-loss group had a much lower 
risk of CHD (HR = 0.66 [0.49–0.89]) and myocardial infarction 
(HR = 0.50 [0.31–0.81]). The estimated 7-year risk of CHD was 
2.7% (2.0% to 3.6%) for the weight-loss group, 4.2% (3.9% to 
4.6%) for the weight maintenance group and 5.4% (4.3% to 
6.5%) for the weight gain group (Figure 4). The RD between 
weight loss versus maintenance was −1.4% (−2.4% to −0.6%). 
In contrast, individuals in the weight-loss group had a higher 
FIGURE 2. Estimated hazard ratios for cardiovascular diseases comparing hypothetical weight change interventions, by BMI 
group. Results from initial analysis as well from the sensitivity analysis, in which a set of chronic diseasesa was assumed to occur 
1, 2, or 3 years before the recorded date.
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risk for stroke (Figure  3, HR = 1.51 [1.00–2.27]). Estimates 
were similar with additional adjustment for IMD, ethnicity, or 
physical activity (eAppendix and eFigure 4; http://links.lww.
com/EDE/B828). However, hazard ratios for CVD comparing 
weight loss to weight maintenance differed by sex (in eFigure 
5; http://links.lww.com/EDE/B828, HR = 1.03 [0.79–1.34] in 
men and HR = 0.65 [0.43–1.01] in women) and age (HR = 0.83 
[0.61–1.14] in individuals aged 45–59 and HR = 1.03 [0.73–
1.46] in individuals aged 60–69). Moreover, estimated hazard 
ratios comparing weight loss to weight maintenance decreased 
with increasing lags for chronic disease records (HR = 0.93 
[0.73–1.18] under 1-year lag, 0.84 [0.63–1.11] under 2-year 
lag, and 0.74 [0.52–1.05] under 3-year lag; Figure 2).
Positive and Negative Control Outcomes
In analyses of diabetes as a positive control outcome, 
the cumulative risk was higher in the weight-loss group than 
in weight maintenance group during the first 2–3 years, in all 
BMI groups (eFigure 6; http://links.lww.com/EDE/B828). 
The corresponding hazard ratios of weight loss (vs weight 
maintenance) were, across BMI groups, positive up to the first 
3 years [HR = 1.39 (0.96–2.00), HR = 1.53 (1.27–1.93) and 
HR = 1.32 (1.13–1.54) in the normal weight, overweight, and 
individuals with obesity respectively], and negative after the 
third year [HR = 0.76 (0.38–1.53), HR = 0.88 (0.60–1.28), and 
HR = 0.64 (0.46–0.88) in the normal weight, overweight and 
individuals with obesity, respectively]. In analyses of nonmel-
anoma skin cancer as a negative outcome control, the hazard 
ratios of both weight gain and weight loss were close to one 
(eFigure 7; http://links.lww.com/EDE/B828).
Other Sensitivity Analyses
Results remained largely the same when we reanalyzed 
the data1 using different cutoffs for the weight gain (3–10% 
gain per year) and loss (3–10% loss per year) arms (eFigure 
8; http://links.lww.com/EDE/B828)2 and after additionally 
adjusting for calendar year (eFigure 9; http://links.lww.com/
EDE/B828). Moreover, the results in the obese nonsmokers 
(eFigure 10; http://links.lww.com/EDE/B828) were similar to 
the ones in the obese overall; nevertheless, this analysis was 
less powered due to the reduced sample size.
DISCUSSION
In this study, we used large-scale EHR data to emulate 
target trials of weight loss, maintenance and gain interven-
tions, estimating their effect on incident CVD. We found that, 
among normal-weight individuals, the weight maintenance 
group had a lower CVD risk compared with the weight gain 
and the weight-loss group. Among individuals with over-
weight, the weight loss and weight gain groups had a slightly 
higher CVD risk compared with weight maintenance; how-
ever, this finding was not robust in sensitivity analyses for 
unmeasured confounding by preclinical diseases. Among 
individuals with obesity, the weight-loss group had a lower 
risk of CHD but not for stroke, heart failure, and CVD deaths.
Strengths and Limitations
Key strengths of this study include the use of large-scale 
EHR and the application of cutting-edge causal inference 
methods,9-12 the combination of which gave us the opportunity 
to emulate weight change trials in 138,567 otherwise healthy 
FIGURE 3. Estimated hazard ratios for cardiovascular diseases (secondary outcomes) comparing hypothetical weight change 
interventions, using pooled logistic regression.
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individuals by BMI group. Such large target trials would be 
impossible to conduct, as most of the actual trials recruit peo-
ple with chronic disease and do not follow them up for suf-
ficient time to measure hard outcomes, like CVD.3 Another 
advantage of this paper is that in previous studies focusing on 
the effect of BMI change, not in the trial emulation framework, 
different methodologies have been used to define baseline and 
then to adjust for baseline confounders. We present in another 
FIGURE 4. Cumulative incidence curvesa for composite CVD and coronary diseases under hypothetical weight change interven-
tions, by BMI group.
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paper in detail why the definition of a baseline period25 mini-
mizes the risk of inappropriate nonadjustment for confound-
ers and why the trial emulation framework is the optimal way 
of estimating the relationship between a risk factor’s change 
and a health outcome. Moreover, the positive and the negative 
control outcome were very important to find potential prob-
lems in the confounding structure of the data. In our case, the 
paradoxical findings of the positive control outcome (i.e., that 
weight loss is a risk factor for diabetes in the first 3 years) 
were explained by reverse causation (actual date of diabetes 
was before the recorded date) and lead our sensitivity analysis, 
in which we assumed that the actual date of chronic diseases 
was 1, 2, and 3 years before the recorded date.
Several limitations should be noted. The observational 
study design of this research, despite our use of causal infer-
ence methods, is still prone to unmeasured confounding. 
We tried to observe to what extent the bias due to preclini-
cal diseases would affect our results by emulating the same 
interventions using positive and negative control outcomes. 
We observed that weight loss was related to higher risk for 
diabetes, compared with weight maintenance, during the 
first 2–3 years. This unexpected result may be due to unmea-
sured confounding by subclinical disease (i.e., reverse causa-
tion). This was an indication that individuals who developed 
a chronic disease during the first 3 years of follow-up might 
not had been healthy at baseline. To address this problem, we 
considered that the actual date of the occurrence of a chronic 
condition was 1, 2, or 3 years before the recorded date and 
observed whether there was any specific trend in our find-
ings from this sensitivity analysis. Moreover, it is important 
to mention that we could not identify the way different people 
lost, maintained, or gained weight (e.g., diet, physical activ-
ity), as our hypothetical interventions are not well defined. 
Different methods of modifying bodyweight may have differ-
ent effects on CVD risk.26 Ill-defined interventions also affect 
our ability to define and address confounding too. Our results 
can be viewed as estimates for an effect of a weighted average 
of several specific strategies that result in bodyweight change 
with (unknown) weights reflecting their frequency in our pop-
ulation.27 Furthermore, we could only identify at which arm 
individuals were allocated only at the end of the first year, 
based on their observed weight trajectory (Appendix, Section 
1; http://links.lww.com/EDE/B828). In this study, as well as 
in similar hypothetical interventions,17,18 each time point cor-
responds to a specific time period (1 year in our study, that is 
baseline, is the baseline period between recruitment and the 
end of the first year). For more details, see Appendix; http://
links.lww.com/EDE/B828, Section 6, as well as in our new 
paper, in which we explain how to estimate a risk factor’s 
change on a health outcome.25 Moreover, we assumed that 
(a) the last observation carried forward9 for at most 4 years 
for smoking status and (b) there was a linear trend for weight 
change between two bodyweight measurements recorded less 
than 4 years apart. Additionally, we could not identify whether 
weight change was intentional and we did not use a sequen-
tial nested structure adding other calendar years to recruit the 
same patients in the future9 to avoid further computational 
complexities, as our sample size was large. Another limita-
tion was that the weight loss and gain categories were rather 
broad (3–20% of annual weight loss and gain, respectively); 
however, when we tightened the cutoffs (3–10%), results 
were practically unchanged. Finally, there might be a risk of 
extending inferences to the general healthy population28 due 
to selection bias because many people do not measure their 
bodyweight frequently and thus were excluded from the study.
Meaning of the Study: Possible Explanations and 
Implications
In our study, the average (SD) percentage of weight 
change during the first year in the weight-loss arm was −5.3% 
(2.3%) in the normal weight, −5.5% (2.6%) in the overweight, 
and −6.1% (3.1%) in the obese. In the United Kingdom, the 
NHS weight-loss guide includes increased levels of physical 
activity and a calorie limit of no more than 1,900 kcal a day 
for most men and 1,400 kcal for most women.29
First, we observed that weight maintenance, compared 
with weight loss or gain, was linked with lower risk for all the 
CVD endpoints in normal-weight individuals. These results 
were in line with the cohort studies that have shown that nor-
mal-weight individuals have less risk for developing CVD7 
compared with the other BMI group and thus infer that these 
individuals should not gain or lose weight.
Among individuals with overweight, we initially found 
evidence consistent with the hypothesis that both weight gain 
and loss moderately increases CVD risk; however, estimates 
were attenuated (especially for weight loss) in sensitivity 
analyses when we assumed that a chronic disease might have 
occurred before the recorded date. These findings are similar 
to those of two previous studies.18,19 In the first study,18 over-
weight and obese individuals were merged together, although 
in the second,19 the authors’ inability to capture a protective 
association might have been due to the moderate sample size.
In people with obesity, weight gain was related to 
a higher risk for CVD, which is in line with the numerous 
reports that have linked high BMI to the onset of CVD.7 
Weight loss was not related to a clear CVD risk reduction, 
even though in the sensitivity analysis, we observed that the 
more years, we assumed the set of chronic diseases happened 
before the recorded date, the lower the hazard ratio for CVD 
of the weight loss was. When we stratified the analysis by 
age and sex, we found that lower risk of CVD for women 
and younger individuals. Furthermore, weight loss was 
related to lower risk for CHD and especially to fatal and non-
fatal myocardial infarction. Individuals with obesity should 
reduce their body weight to lower their risk for CHD. The US 
Preventive Services Task Force currently recommends behav-
ioral weight-loss interventions for individuals with obesity 
(BMI ≥ 30 kg/m2).30 Nevertheless, the expected beneficial 
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effect from weight reduction was only detectable for CHD, 
but not for stroke, in our study. Although the American 
Stroke Association recommends weight loss for people with 
overweight or obesity for the primary prevention of ischemic 
stroke,31 we did not estimate any benefit from weight reduc-
tion. This may be due to the fact that BMI is an imprecise 
measure of body fat and does not distinguish between fat and 
muscle mass.
Unanswered Questions and Future Research
Our study could not clarify how individuals lost, main-
tained, or gained weight. More studies should focus on how 
to emulate trials from observational data to investigate how 
adherence to different diets or physical activity levels that 
result in weight change could affect a range of CVD outcomes.
CONCLUSIONS
Individuals who maintained their weight had the lowest 
risk for CVD among those with normal weight. Among indi-
viduals with obesity, the weight-loss group had a lower risk of 
CHD. Weight gain was associated with increased risk of CVD 
across BMI groups. The paradoxical findings that weight 
loss was associated with increased risk for diabetes (posi-
tive control outcome) in the first 3 years [HR = 1.39 (0.96–
2.00), HR = 1.53 (1.27–1.93), and HR = 1.32 (1.13–1.54) in 
TABLE 2. Characteristics of Individuals at Baseline and During the First Year, by BMI Group and Hypothetical Weight Change 
Intervention
 
A. Intervention in Normal-weight 
Individuals (N = 45,938)
B. Intervention in Overweight  
Individuals (N = 57,682)
C. Intervention in Obese  
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Prevalence of hypertensives; % 26% 23% 21% 32% 30% 27% 37% 34% 31%
Record of high LDL levels (before baseline)a 6% 6% 5% 10% 9% 8% 10% 9% 8%
Use of diuretics (before baseline); % 10% 8% 10% 14% 12% 14% 20% 18% 19%
Family history of CVD; % 13% 13% 13% 13% 13% 13% 12% 12% 12%


















Hypertensive (during the first year); % 17% 15% 15% 24% 21% 19% 29% 26% 23%
High LDL levelsa
(during the first year); %
6% 5% 4% 9% 7% 6% 9% 7% 6%
Use of diuretics
(during the first year); %
9% 7% 9% 13% 12% 14% 19% 18% 19%
Smoking status
(during the first year)
         
 Never 53% 59% 54% 53% 55% 51% 53% 54% 51%
 Former 22% 22% 23% 29% 29% 29% 32% 32% 31%
 Current 26% 19% 24% 18% 16% 20% 15% 15% 18%
Weight measurements
(during the first year)
         
 1 meas., % 66% 85% 72% 61% 82% 70% 52% 74% 63%
 2 meas., % 26% 13% 22% 28% 14% 24% 30% 19% 28%
 3–5 meas., % 8% 3% 6% 11% 4% 6% 18% 7% 9%
Clinical consultations
(during the first year)
         
 1–2 consultations, % 24% 29% 26% 21% 27% 23% 17% 23% 21%
 3–5 consultations, % 34% 38% 37% 36% 36% 36% 35% 36% 34%
 6–8 consultations, % 25% 22% 24% 27% 24% 26% 29% 26% 27%
 9–11 consultations, % 17% 11% 14% 16% 13% 15% 18% 15% 17%
aIndividuals with previous LDL records >4.1 mmol/L (high LDL).
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the normal weight, overweight, and individuals with obe-
sity, respectively] guided our sensitivity analysis in which 
we assumed that the actual date of chronic diseases was 1, 2, 
and 3 years before the recorded date. Our results may help to 
inform policy guidelines for cardiovascular prevention.
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